GlassScriptPhysician profile
Anshul B Bamrolia
NPI 1942361662
$877.37
in general payments reported to CMS, 2019-2025
13 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $13.01 · 2021: $11.92 · 2022: $181 · 2023: $90.59 · 2024: $68.87 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.43 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $289.70 | 2019-2025 | Rybrevant |
| Merck Sharp & Dohme LLC | $204.61 | 2019-2025 | Lynparza, Keytruda |
| Novartis Pharmaceuticals Corporation | $109.95 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $61.01 | 2023-2025 | Zepzelca |
| Lilly USA, LLC | $51.67 | 2019-2024 | |
| Emd Serono, INC. | $39.57 | 2019-2020 | |
| Abbvie INC. | $24.42 | 2025 | |
| Celgene Corporation | $19.76 | 2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $17.31 | 2022 | |
| Pfizer INC. | $16.94 | 2019 | |
| Genzyme Corporation | $15.48 | 2022 | |
| Genentech USA, INC. | $15.03 | 2025 | Itovebi |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshul Bamrolia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.